genomic footprinting for predicting the clinical response to cancer therapy in colorectal cancer.

摘要

The present invention relates to an in vitro method for predicting the clinical response of a patient diagnosed with colorectal cancer to a cancer therapy or to identify a patient diagnosed with colorectal cancer with low likelihood of responding to treatment with antitumor therapy patient patient, preferably neoadjuvant cancer therapy, comprising detecting expression levels of a genomic fingerprint consists of six genes. Furthermore, the invention also relates to kits for implementing said method.